ホーム › 肺がん › ニューヨーク › New York City
New York City、NYにおける肺がんの臨床試験
New York Cityとその周辺地域（約30マイル以内）の拠点で、肺がんに関する60件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of ZW251 in Participants With Advanced Solid Tumors
被験者募集中第1相
- Memorial Sloan Kettering Cancer Center, New York
A Study of Mental Health Care in People With Cancer
被験者募集中
- Memorial Sloan Kettering Cancer Center, New York
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
被験者募集中第1/2相
- Memorial Sloan Kettering (Melanoma/NSCLC), New York
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
被験者募集中第3相
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Empathic Communication Skills (ECS) Training
被験者募集中健康なボランティア歓迎
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- Memorial Sloan Kettering Hospital, New York
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
被験者募集中第1相
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
被験者募集中第3相
- NYU Langone's Perlmutter Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
被験者募集中第3相
- Memorial Sloan Kettering Cancer Center, New York
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center, New York
A Registry for People With Lung Cancer
被験者募集中観察研究
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
被験者募集中第2/3相
- NYU Langone Health, New York
- Weill Cornell Medical College, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
被験者募集中第1/2相
- NYU Langone Health Perlmutter Cancer Center, New York
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
被験者募集中第1/2相
- Memorial Sloan Kettering Cancer Center, New York
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
被験者募集中第1相
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
被験者募集中第1/2相
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Memorial Sloan Kettering Cancer Center, New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Laura and Isaac Perlmutter Cancer Center, New York
- Manhattan Eye, Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
被験者募集中第1相
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, New York
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
被験者募集中第1相
- Perlmutter Cancer Center - NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
被験者募集中第3相
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
被験者募集中第3相
- Cornell University - NewYork-Presbyterian/Weill Cornell Medical Center, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
被験者募集中第1相
- New York Cancer & Blood Specialists, New York
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
被験者募集中第3相
- New York Proton Center, New York
- Manhattan Eye Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
- 他1件
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
被験者募集中第3相
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- New York Proton Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Lung Cancer Risk
被験者募集中観察研究健康なボランティア歓迎
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
被験者募集中第2相
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
被験者募集中第1相
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Study of a Side Effects and Resource Navigation Program for People With Cancer
被験者募集中
- City College of New York (Data Collection AND Specimen Analysis), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
被験者募集中第1/2相
- New York University Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
被験者募集中第2相
- New York University Langone Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- NYU Langone Medical Center, New York
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
被験者募集中第1/2相
- Weill Medical College of Cornell University, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
被験者募集中第1相
- Research Site, New York
- Research Site, New York
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Columbia University, New York
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
被験者募集中第1/2相
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Brodalumab in the Treatment of Immune-Related Adverse Events
被験者募集中第1相
- Columbia University Irving Medical Center, New York
Lung Cancer Biomarkers and Screening
被験者募集中観察研究健康なボランティア歓迎
- NYU Cancer Institute at New York University Medical Center, New York
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
被験者募集中第1/2相
- Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
被験者募集中第2相
- Weill Cornell Medicine, New York
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
被験者募集中第1/2相
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Confocal Laser Endomicroscopy VERification
被験者募集中
- Montefiore Medical Center, New York
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
被験者募集中観察研究
- Manhattan Eye Ear and Throat Hospital, New York
- Lenox Hill Hospital, New York
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
被験者募集中第1/2相
- Weill Cornell Medicine, Cornell University (site 126), New York
Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer
被験者募集中観察研究
- NYU Langone Health, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- NYU Langone Health, New York
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
被験者募集中第2相
- NYU Langone Health, New York
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
被験者募集中観察研究
- Icahn School of Medicine at Mount Sinai, New York
Comprehensive Outcomes for After Cancer Health
被験者募集中健康なボランティア歓迎
- Memorial Sloan Kettering Cancer Center, New York
他の都市における肺がんの試験
- Houston, TX78件の研究
- Boston, MA62件の研究
- Los Angeles, CA45件の研究
- Arlington, VA41件の研究
- Washington, DC41件の研究
- Chicago, IL41件の研究
- Nashville, TN40件の研究
- Baltimore, MD40件の研究
- St. Louis, MO39件の研究
- Columbus, OH37件の研究
- Philadelphia, PA36件の研究
- Seattle, WA33件の研究
New York Cityにおける他の研究
- 乳がん136件の研究
- 非小細胞肺癌121件の研究
- がん（全種類）109件の研究
- 前立腺がん103件の研究
- 転移性癌93件の研究
- 大腸癌78件の研究
- 卵巣がん69件の研究
- 多発性骨髄腫60件の研究
- 膵臓がん60件の研究
- 子宮内膜がん52件の研究
- 急性骨髄性白血病51件の研究
- 心不全51件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。